Thymic origin of some natural killer cells

clonal proliferation of human CD3-16+ cells from CD3-4-8- thymocyte precursors requires the presence of H9 leukemic cells

Maria Cristina Mingari, Alessandro Poggi, Rosanna Bellomo, Nicoletta Pella, Lorenzo Moretta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purified CD3-4- thymocyte populations were cultured in the presenceof interleukin-2 (IL-2) and peripheral blood lymphocytes (PBL) and/or tumor cell lines as a source of irradiated feeder cells. Maximal cell proliferation was obtained in the presence of a mixture of H9 leukemic cells and normal PBL. More importantly, under these culture conditions 30%-50% of these cells were found to express CD16 surface antigen after 1-2 weeks of culture. Similar proportions of CD16+ cells could be detected in CD3-4- thymocyte populations that had been further depleted of CD16+ cells. Cloning of CD3-4-16- thymocytes under limiting dilution conditions resulted, in the presence of H9 cells, in more than 50% of CD16+ clones (cloning efficiency 3%-8%). Since some of the surface CD3- clones expressed cytoplasmic CD3 antigen, it has been possible to identify four distinct phenotypic groups of clones (CD16+ cyCD3+, CD16+ cyCD3-, CD16- cyCD3+, CD16- cyCD3-). Independently of their phenotype, all thymus-derived CD3- clones expressed a strong cytolytic activity against natural killer (NK)-sensitive and NK-resistant tumour target cells. In addition, following stimulation with phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (or PHA alone) all clones released interferon-γ and tumour necrosis factor-α, but not IL-2. Taken together, our data provide evidence that cells which share their phenotypic and functional properties with CD3- CD16+ NK cells can be derived from thymic precursors.

Original languageEnglish
Pages (from-to)176-178
Number of pages3
JournalInternational Journal of Clinical & Laboratory Research
Volume21
Issue number2-4
DOIs
Publication statusPublished - Jun 1992

Fingerprint

Cloning
Thymocytes
Natural Killer Cells
Organism Cloning
Cell Proliferation
Lymphocytes
Phytohemagglutinins
Interleukin-2
Tumors
Blood
CD3 Antigens
Feeder Cells
Thymus
IgG Receptors
Cell proliferation
Surface Antigens
Cell culture
Interferons
Dilution
Tumor Cell Line

Keywords

  • CD3 CD16 cells
  • CD348 precursors
  • H9 leukaemic cells
  • Natural killer cells
  • Thymic origin

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

@article{cdbd477229164166ba6b62f448ee948c,
title = "Thymic origin of some natural killer cells: clonal proliferation of human CD3-16+ cells from CD3-4-8- thymocyte precursors requires the presence of H9 leukemic cells",
abstract = "Purified CD3-4- thymocyte populations were cultured in the presenceof interleukin-2 (IL-2) and peripheral blood lymphocytes (PBL) and/or tumor cell lines as a source of irradiated feeder cells. Maximal cell proliferation was obtained in the presence of a mixture of H9 leukemic cells and normal PBL. More importantly, under these culture conditions 30{\%}-50{\%} of these cells were found to express CD16 surface antigen after 1-2 weeks of culture. Similar proportions of CD16+ cells could be detected in CD3-4- thymocyte populations that had been further depleted of CD16+ cells. Cloning of CD3-4-16- thymocytes under limiting dilution conditions resulted, in the presence of H9 cells, in more than 50{\%} of CD16+ clones (cloning efficiency 3{\%}-8{\%}). Since some of the surface CD3- clones expressed cytoplasmic CD3 antigen, it has been possible to identify four distinct phenotypic groups of clones (CD16+ cyCD3+, CD16+ cyCD3-, CD16- cyCD3+, CD16- cyCD3-). Independently of their phenotype, all thymus-derived CD3- clones expressed a strong cytolytic activity against natural killer (NK)-sensitive and NK-resistant tumour target cells. In addition, following stimulation with phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (or PHA alone) all clones released interferon-γ and tumour necrosis factor-α, but not IL-2. Taken together, our data provide evidence that cells which share their phenotypic and functional properties with CD3- CD16+ NK cells can be derived from thymic precursors.",
keywords = "CD3 CD16 cells, CD348 precursors, H9 leukaemic cells, Natural killer cells, Thymic origin",
author = "Mingari, {Maria Cristina} and Alessandro Poggi and Rosanna Bellomo and Nicoletta Pella and Lorenzo Moretta",
year = "1992",
month = "6",
doi = "10.1007/BF02591639",
language = "English",
volume = "21",
pages = "176--178",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "2-4",

}

TY - JOUR

T1 - Thymic origin of some natural killer cells

T2 - clonal proliferation of human CD3-16+ cells from CD3-4-8- thymocyte precursors requires the presence of H9 leukemic cells

AU - Mingari, Maria Cristina

AU - Poggi, Alessandro

AU - Bellomo, Rosanna

AU - Pella, Nicoletta

AU - Moretta, Lorenzo

PY - 1992/6

Y1 - 1992/6

N2 - Purified CD3-4- thymocyte populations were cultured in the presenceof interleukin-2 (IL-2) and peripheral blood lymphocytes (PBL) and/or tumor cell lines as a source of irradiated feeder cells. Maximal cell proliferation was obtained in the presence of a mixture of H9 leukemic cells and normal PBL. More importantly, under these culture conditions 30%-50% of these cells were found to express CD16 surface antigen after 1-2 weeks of culture. Similar proportions of CD16+ cells could be detected in CD3-4- thymocyte populations that had been further depleted of CD16+ cells. Cloning of CD3-4-16- thymocytes under limiting dilution conditions resulted, in the presence of H9 cells, in more than 50% of CD16+ clones (cloning efficiency 3%-8%). Since some of the surface CD3- clones expressed cytoplasmic CD3 antigen, it has been possible to identify four distinct phenotypic groups of clones (CD16+ cyCD3+, CD16+ cyCD3-, CD16- cyCD3+, CD16- cyCD3-). Independently of their phenotype, all thymus-derived CD3- clones expressed a strong cytolytic activity against natural killer (NK)-sensitive and NK-resistant tumour target cells. In addition, following stimulation with phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (or PHA alone) all clones released interferon-γ and tumour necrosis factor-α, but not IL-2. Taken together, our data provide evidence that cells which share their phenotypic and functional properties with CD3- CD16+ NK cells can be derived from thymic precursors.

AB - Purified CD3-4- thymocyte populations were cultured in the presenceof interleukin-2 (IL-2) and peripheral blood lymphocytes (PBL) and/or tumor cell lines as a source of irradiated feeder cells. Maximal cell proliferation was obtained in the presence of a mixture of H9 leukemic cells and normal PBL. More importantly, under these culture conditions 30%-50% of these cells were found to express CD16 surface antigen after 1-2 weeks of culture. Similar proportions of CD16+ cells could be detected in CD3-4- thymocyte populations that had been further depleted of CD16+ cells. Cloning of CD3-4-16- thymocytes under limiting dilution conditions resulted, in the presence of H9 cells, in more than 50% of CD16+ clones (cloning efficiency 3%-8%). Since some of the surface CD3- clones expressed cytoplasmic CD3 antigen, it has been possible to identify four distinct phenotypic groups of clones (CD16+ cyCD3+, CD16+ cyCD3-, CD16- cyCD3+, CD16- cyCD3-). Independently of their phenotype, all thymus-derived CD3- clones expressed a strong cytolytic activity against natural killer (NK)-sensitive and NK-resistant tumour target cells. In addition, following stimulation with phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (or PHA alone) all clones released interferon-γ and tumour necrosis factor-α, but not IL-2. Taken together, our data provide evidence that cells which share their phenotypic and functional properties with CD3- CD16+ NK cells can be derived from thymic precursors.

KW - CD3 CD16 cells

KW - CD348 precursors

KW - H9 leukaemic cells

KW - Natural killer cells

KW - Thymic origin

UR - http://www.scopus.com/inward/record.url?scp=0026306328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026306328&partnerID=8YFLogxK

U2 - 10.1007/BF02591639

DO - 10.1007/BF02591639

M3 - Article

VL - 21

SP - 176

EP - 178

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 2-4

ER -